Cassava Sciences, Inc. (FRA:PX91)

Market Cap	80.91M -36.3%
Revenue (ttm)	n/a
Net Income	-90.37M
EPS	-1.87
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	69
Open	1.823
Previous Close	1.668
Day's Range	1.823 - 1.823
52-Week Range	1.030 - 3.902
Beta	n/a
RSI	39.27
Earnings Date	Mar 3, 2026

About Cassava Sciences

Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. Cassava Sciences, Inc. was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. The company was incorporated in 1998 and is based in Austin, Te...

• Industry: Pharmaceutical Preparations
• Founded: 1998
• Employees: 30
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: PX91

Financial Performance

Financial numbers in USD